Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238561902> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4238561902 endingPage "2" @default.
- W4238561902 startingPage "2" @default.
- W4238561902 abstract "On July 2, UK-based GlaxoSmithKine (GSK) agreed to plead guilty to criminal charges of fraudulent promotion of its drugs and pay the US Government a settlement of US$3 billion. If accepted, this will be the largest fine imposed on a drug company, surpassing the $2·3 billion paid by Pfizer for inappropriate marketing in 2009. The amount adds to GSK's $750 million settlement in 2010 over manufacturing quality. What is particularly egregious about GSK's fraud is the calculated deceit and potential human cost of its aggressive and misleading marketing. For instance, while evidence was emerging that showed an increased suicide risk in adolescents prescribed selective serotonin reuptake inhibitors for depression, GSK was actively encouraging off-label prescription of paroxetine to individuals younger than 18 years. This was not an isolated incident; off-label use was also encouraged for bupropion. For rosiglitazone, safety data were withheld from the US Food and Drug Administration and altered, potentially delaying restrictions on the drug's use and putting people to whom it was prescribed at increased risk of cardiovascular complications. The company is also accused of cheating Medicare. Such behaviour is not only illegal, it is immoral. As Machiavelli observed, “he who seeks to deceive will always find someone who will allow himself to be deceived”. Sadly, in the case of GSK, this has involved doctors who were all too ready to be beguiled by illegal kickbacks and lavish hospitality. Multibillion-dollar fines are inadequate to tackle misconduct when penalties can be paid from post-tax profits. Indeed, there seems to be such an arrogance about money, that on the same day that GSK was being fined $3 billion, the Association of the British Pharmaceutical Industry argued that the UK Government should reinvest the $5 billion expected from NHS drug savings back into the industry. GSK and other drug companies have come adrift from the standards of the societies they seek to serve. They need to rediscover corporate citizenship, beginning with the individual integrity and accountability of their employees." @default.
- W4238561902 created "2022-05-12" @default.
- W4238561902 creator A5085953656 @default.
- W4238561902 date "2012-07-01" @default.
- W4238561902 modified "2023-09-30" @default.
- W4238561902 title "Moral decay at GSK reaps record US$3 billion fine" @default.
- W4238561902 doi "https://doi.org/10.1016/s0140-6736(12)61110-6" @default.
- W4238561902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22770442" @default.
- W4238561902 hasPublicationYear "2012" @default.
- W4238561902 type Work @default.
- W4238561902 citedByCount "0" @default.
- W4238561902 crossrefType "journal-article" @default.
- W4238561902 hasAuthorship W4238561902A5085953656 @default.
- W4238561902 hasBestOaLocation W42385619021 @default.
- W4238561902 hasConcept C10138342 @default.
- W4238561902 hasConcept C109168655 @default.
- W4238561902 hasConcept C138885662 @default.
- W4238561902 hasConcept C144133560 @default.
- W4238561902 hasConcept C145097563 @default.
- W4238561902 hasConcept C15744967 @default.
- W4238561902 hasConcept C17744445 @default.
- W4238561902 hasConcept C195487862 @default.
- W4238561902 hasConcept C199539241 @default.
- W4238561902 hasConcept C2777063073 @default.
- W4238561902 hasConcept C2778137410 @default.
- W4238561902 hasConcept C2780587575 @default.
- W4238561902 hasConcept C41895202 @default.
- W4238561902 hasConcept C71924100 @default.
- W4238561902 hasConcept C73484699 @default.
- W4238561902 hasConcept C94625758 @default.
- W4238561902 hasConcept C98147612 @default.
- W4238561902 hasConceptScore W4238561902C10138342 @default.
- W4238561902 hasConceptScore W4238561902C109168655 @default.
- W4238561902 hasConceptScore W4238561902C138885662 @default.
- W4238561902 hasConceptScore W4238561902C144133560 @default.
- W4238561902 hasConceptScore W4238561902C145097563 @default.
- W4238561902 hasConceptScore W4238561902C15744967 @default.
- W4238561902 hasConceptScore W4238561902C17744445 @default.
- W4238561902 hasConceptScore W4238561902C195487862 @default.
- W4238561902 hasConceptScore W4238561902C199539241 @default.
- W4238561902 hasConceptScore W4238561902C2777063073 @default.
- W4238561902 hasConceptScore W4238561902C2778137410 @default.
- W4238561902 hasConceptScore W4238561902C2780587575 @default.
- W4238561902 hasConceptScore W4238561902C41895202 @default.
- W4238561902 hasConceptScore W4238561902C71924100 @default.
- W4238561902 hasConceptScore W4238561902C73484699 @default.
- W4238561902 hasConceptScore W4238561902C94625758 @default.
- W4238561902 hasConceptScore W4238561902C98147612 @default.
- W4238561902 hasIssue "9836" @default.
- W4238561902 hasLocation W42385619021 @default.
- W4238561902 hasLocation W42385619022 @default.
- W4238561902 hasOpenAccess W4238561902 @default.
- W4238561902 hasPrimaryLocation W42385619021 @default.
- W4238561902 hasRelatedWork W1535824739 @default.
- W4238561902 hasRelatedWork W174545909 @default.
- W4238561902 hasRelatedWork W1948675150 @default.
- W4238561902 hasRelatedWork W2152310902 @default.
- W4238561902 hasRelatedWork W2265668670 @default.
- W4238561902 hasRelatedWork W2462648204 @default.
- W4238561902 hasRelatedWork W2785137431 @default.
- W4238561902 hasRelatedWork W2903749241 @default.
- W4238561902 hasRelatedWork W2980455371 @default.
- W4238561902 hasRelatedWork W828138101 @default.
- W4238561902 hasVolume "380" @default.
- W4238561902 isParatext "false" @default.
- W4238561902 isRetracted "false" @default.
- W4238561902 workType "article" @default.